Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.71 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.67 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.62 |
| ▸ | FPGS | Q05932 | 2/20 | 0.60 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
| ▸ | GART | P22102 | 5/20 | 0.55 |
| ▸ | ATIC | P31939 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucovorin SCHEMBL159828 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL4575698 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Levoleucovorin SCHEMBL639769 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL3031362 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL29616563 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL29385578 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL29379632 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL36113 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL21498299 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL4744838 | 0.99 | DHFR (0.98) | DHFRLMNAMTHFD1SOSTMTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318395-B2 | Ethinyl estradiol-β-cyclodextrin complex and process for preparing thereof | LABORATORIOS LEON FARMA, S.A. (ES) | 2025-06-03 | — | — | US | claimed |
| US-20240415837-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2024-12-19 | — | — | US | claimed |
| US-12138266-B2 | Folate preparations | APROFOL AG (CH) | 2024-11-12 | — | — | US | claimed |
| EP-4419107-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | Machover, David (FR) | 2024-08-28 | — | — | EP | claimed |
| US-12048702-B2 | Folate preparations | APROFOL AG (CH) | 2024-07-30 | — | — | US | claimed |
| US-20230277544-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2023-09-07 | — | — | US | claimed |
| US-11690846-B2 | Folate salts for medical use | APROFOL AG | 2023-07-04 | — | — | US | claimed |
| US-20230158029-A1 | FOLATE COMPOSITIONS | APROFOL AG (CH) | 2023-05-25 | — | — | US | claimed |
| WO-2023066865-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2023-04-27 | — | — | WO | claimed |
| EP-4114399-A1 | FOLATE PREPARATIONS FOR THE TREATMENT OF OCULAR DISEASES | Aprofol AG (CH) | 2023-01-11 | — | — | EP | claimed |
| EP-0898965-A2 | Use of tetrahydrofolates for modulating the homocysteine level | EPROVA Aktiengesellschaft (CH) | 1999-03-03 | — | — | EP | claimed |
| CN-1205206-A | Use of natural stereoisomers of tetrahydrofolic acid for producing pharmaceutical preparations | EPROVA AG (CH) | 1999-01-20 | — | — | CN | claimed |
| EP-0877563-A1 | FOOD AND VITAMIN PREPARATIONS CONTAINING THE NATURAL ISOMER OF REDUCED FOLATES | South Alabama Medical Science Foundation (US) | 1998-11-18 | — | — | EP | claimed |
| WO-1997027764-A1 | FOOD AND VITAMIN PREPARATIONS CONTAINING THE NATURAL ISOMER OF REDUCED FOLATES | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1997-08-07 | — | — | WO | claimed |
| CN-1032206-C | Process for preparing tetrahydrofolic acid | EPROVA AG (CH) | 1996-07-03 | — | — | CN | claimed |
| EP-0348641-B1 | Process for the preparation of tetrahydrofolates | EPROVA AG (CH) | 1995-06-21 | — | — | EP | claimed |
| US-5198547-A | Process for N5-formylating tetrahydropteridines | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION, USA (US) | 1993-03-30 | — | — | US | claimed |
| US-5006655-A | Process for the preparation of tetrahydrofolates | EPROVA AG (CH) | 1991-04-09 | — | — | US | claimed |
| CN-1038813-A | The method for preparing tetrahydrofolate | EPROVA AG (CH) | 1990-01-17 | — | — | CN | claimed |
| EP-0348641-A2 | Process for the preparation of tetrahydrofolates | EPROVA Aktiengesellschaft (CH) | 1990-01-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690846-B2 | Folate salts for medical use | FOLR2, FOLR1, MTHFD1 | DHFR 10/4885LMNA 4414/4885MTHFD1 3/4885 |
| US-20230277544-A1 | FOLATE SALTS FOR MEDICAL USE | FOLR2, FOLR1, MTHFD1 | DHFR 10/4885LMNA 4175/4885MTHFD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.